Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Cyteir Therapeutics (NASDAQ: CYT) reported its fourth quarter and full year 2022 financial results, revealing a net loss of $8.8 million for Q4 2022, a decrease from $11.8 million in Q4 2021. The full year net loss was $46.1 million, compared to $42.1 million in 2021. Cyteir ended 2022 with $147.1 million in cash, funding operations into 2026. The company is prioritizing the clinical development of CYT-0851 for advanced ovarian cancer, with preliminary data from Phase 1 combination trials expected in mid-2023. R&D expenses for 2022 increased to $34.6 million, while G&A expenses rose to $13.5 million. The firm has halted discovery projects to focus on CYT-0851.
- Encouraging preliminary clinical activity reported for CYT-0851 in ovarian cancer.
- Strong cash position of $147.1 million funding operations into 2026.
- Plans for potential registrational trial of CYT-0851 in 2024.
- Net loss increased to $46.1 million for the full year 2022, up from $42.1 million in 2021.
- G&A expenses rose to $13.5 million, reflecting increased costs associated with being a public company.
- Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023
- Dose for the Phase 1 combination trials identified as 400mg daily
-
Ended 2022 with approximately
$147 million
“We continue to be encouraged by the early clinical activity of CYT-0851 in ovarian cancer and are committed to bringing CYT-0851 to patients,” said
Recent Updates to the CYT-0851 Clinical Program
- In January, Cyteir reported encouraging preliminary clinical activity in the Phase 1 dose escalation cohorts with CYT-0851, an investigational oral monocarboxylate transporter inhibitor, in combination with capecitabine for the treatment of advanced ovarian cancer. Cyteir announced the prioritization of development of CYT-0851 in combination with capecitabine in advanced ovarian cancer and deferred development of additional indications with this combination. Cyteir plans to enroll up to an additional nine patients with advanced ovarian cancer in the capecitabine combination at the 400 mg CYT-0851 dose level. If supported by the data and regulatory feedback, Cyteir intends to pursue development and potential registration of CYT-0851 in combination with capecitabine as an all-oral treatment for platinum resistant ovarian cancer. Preliminary data on the combination with capecitabine are expected to be disclosed in mid-2023.
- Enrollment in the Phase 1 dose escalation cohorts of CYT-0851 in combination with gemcitabine in solid tumors continues. This combination is currently being evaluated at 300 mg of CYT-0851 in combination with gemcitabine, and if deemed tolerable, will advance to 400 mg of CYT-0851 in combination with gemcitabine. Preliminary data from the Phase 1 dose escalation cohorts of CYT-0851 in combination with gemcitabine are expected to be disclosed in mid-2023.
Recent Business Updates
- In conjunction with the prioritization of the clinical plan for CYT-0851, Cyteir also ceased all discovery projects focused on identifying inhibitors of DNA damage repair. Cyteir is pursuing out licensing of its preclinical pipeline.
Fourth Quarter and Full Year 2022 Financial Results
Cash and cash equivalents: Cash and cash equivalents as of
Research and development (R&D) expenses: R&D expenses were
General and administrative (G&A) expenses: G&A expenses were
Net loss: Net loss was
About
Cyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir’s current priority in CYT-0851 development is in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer. Follow Cyteir on social media: LinkedIn and
Forward-Looking Statements
This press release contains “forward-looking statements” about Cyteir’s strategy, future plans, and prospects, including statements regarding the development of Cyteir’s compounds and potential expansion opportunities, regulatory strategy, and path for Cyteir’s compounds, the expected timing and reporting of results of Cyteir’s preclinical and clinical studies, and Cyteir’s expected cash runway. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “project,” “seek,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include: the benefits and potential impact of our portfolio prioritization; expected timing to receive clinical data from current ongoing clinical studies; expected cost savings from our prioritization and reduction in force; and our expected extended cash runway.
Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to: that Cyteir’s clinical trials may fail to demonstrate adequately the safety and efficacy of CYT-0851; that preclinical testing of CYT-0851 may not be predictive of the results or success of clinical trials; that the clinical development of CYT-0851 may be delayed or otherwise take longer and/or cost more than planned; that Cyteir may be unable to initiate, enroll or complete clinical development of CYT-0851; that the continuing global outbreak of COVID-19 (including any resurgences or variants) may result in development or manufacturing delays, supply shortages, or shortages of qualified healthcare personnel; that synthetic lethality, as an emerging class of precision medicine targets, could result in negative perceptions of the efficacy, safety or tolerability of this class of targets, which could adversely affect our ability to conduct our business, advance our drug candidates or obtain regulatory approvals; and that Cyteir’s compounds may not receive regulatory approvals or become commercially successful products. These and other risks and uncertainties are identified under the heading “Risk Factors” in Cyteir’s most recent Annual Report on Form 10-K and other filings Cyteir has made and may make with the
The forward-looking statements contained in this press release are based on management's current views, plans, estimates, assumptions, and projections with respect to future events, and Cyteir does not undertake and specifically disclaims any obligation to update any forward-looking statements.
| Condensed consolidated statements of operations | ||||||||||||
| (in thousands, except share and per share amounts) (unaudited) |
||||||||||||
| Three Months Ended |
Years Ended |
|||||||||||
|
2022 |
|
2021 |
|
2022 |
|
2021 |
|||||
| Operating expenses: | ||||||||||||
| Research and development | $ |
7,470 |
$ |
8,255 |
$ |
34,624 |
$ |
30,959 |
||||
| General and administrative |
|
2,583 |
|
3,607 |
|
13,546 |
|
11,300 |
||||
| Total operating expenses |
|
10,053 |
|
11,862 |
|
48,170 |
|
42,259 |
||||
| Loss from operations |
|
(10,053) |
|
(11,862) |
|
(48,170) |
|
(42,259) |
||||
| Other income (expense): | ||||||||||||
| Other income (expense) |
|
1,260 |
|
47 |
|
2,109 |
|
133 |
||||
| Total other income (expense) |
|
1,260 |
|
47 |
|
2,109 |
|
133 |
||||
| Net loss | $ |
(8,793) |
$ |
(11,815) |
$ |
(46,061) |
$ |
(42,126) |
||||
| Net loss per share—basic and diluted | $ |
(0.25) |
$ |
(0.34) |
$ |
(1.31) |
$ |
(2.16) |
||||
| Weighted-average common stock outstanding—basic and diluted | 35,375,849 |
|
35,136,168 |
|
35,272,831 |
|
19,499,292 |
|||||
| Research and development expenses for the fourth quarter and full year-ended |
||||||||||||
| Condensed consolidated balance sheets | ||||||
| (in thousands, except share and per share amounts) (unaudited) |
||||||
2022 |
2021 |
|||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ |
147,120 |
$ |
189,723 |
||
| Prepaid expenses and other current assets |
|
2,089 |
|
3,354 |
||
| Total current assets | $ |
149,209 |
$ |
193,077 |
||
| Property and equipment, net |
|
1,699 |
|
2,055 |
||
| Other assets |
|
2,324 |
|
256 |
||
| Total assets | $ |
153,232 |
$ |
195,388 |
||
| Liabilities and stockholders’ equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ |
1,128 |
$ |
1,785 |
||
| Accrued expenses and other current liabilities |
|
4,187 |
|
5,726 |
||
| Total current liabilities | $ |
5,315 |
$ |
7,511 |
||
| Deferred rent, net of current portion |
|
- |
|
384 |
||
| Other long term liabilities |
|
1,631 |
|
201 |
||
| Total liabilities | $ |
6,946 |
$ |
8,096 |
||
| Commitments and contingencies (Note 12) | ||||||
| Stockholders’ equity: | ||||||
| Preferred stock, |
|
- |
|
- |
||
| Common stock, |
|
35 |
|
35 |
||
| Additional paid-in capital |
|
284,365 |
|
279,310 |
||
| Accumulated deficit |
|
(138,114) |
|
(92,053) |
||
| Total stockholders’ equity |
|
146,286 |
|
187,292 |
||
| Total liabilities and stockholders’ equity | $ |
153,232 |
$ |
195,388 |
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005237/en/
Cyteir Investor Relations
857-285-4140
ir@cyteir.com
Source:
FAQ
What are the financial results for Cyteir Therapeutics for Q4 and full year 2022?
What is the cash position of Cyteir as of December 31, 2022?
When will preliminary data for CYT-0851 be announced?
What is the focus of Cyteir's clinical development for CYT-0851?
How have expenses changed for Cyteir in 2022?
